Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy after Allogeneic Hematopoietic Cell Transplantation in Relapsed/ Refractory B Cell Non-Hodgkin’s Lymphoma

Ítems similars

• Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 CAR T-cell therapy
  per: Imber, Brandon S., et al.
  Publicat: (2020)
• Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
  per: Lin, Richard J., et al.
  Publicat: (2020)
• Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma
  per: Lin, Richard J., et al.
  Publicat: (2020)
• NCMP-07. CLINICAL NEUROLOGICAL FEATURES AND ELECTROGRAPHIC PATTERNS OF PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL AT MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC)
  per: Sequeira, Alexandra, et al.
  Publicat: (2018)
• Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
  per: Jain, Tania, et al.
  Publicat: (2020)